Cargando…

Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report

Paxlovid has shown the potential decreasing the hospitalization rate of mild or moderate coronavirus disease 2019 (COVID-19) and death in few of clinical trials, and is expected to the most promising medicine targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SRAS-COV-2). However, there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Liulu, Zhang, Shasha, Han, Jing, Yi, Yile, Zhou, Hourong, Li, Jianquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665888/
https://www.ncbi.nlm.nih.gov/pubmed/36397388
http://dx.doi.org/10.1097/MD.0000000000031361
_version_ 1784831383480303616
author Zhang, Liulu
Zhang, Shasha
Han, Jing
Yi, Yile
Zhou, Hourong
Li, Jianquan
author_facet Zhang, Liulu
Zhang, Shasha
Han, Jing
Yi, Yile
Zhou, Hourong
Li, Jianquan
author_sort Zhang, Liulu
collection PubMed
description Paxlovid has shown the potential decreasing the hospitalization rate of mild or moderate coronavirus disease 2019 (COVID-19) and death in few of clinical trials, and is expected to the most promising medicine targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SRAS-COV-2). However, there are no enough evidences to show it effectiveness for all patients with SARS-COV-2, especially among elderly patients and newest Omicron variant. PATIENT CONCERNS AND DIAGNOSIS: A 79 year’s old female patient was admitted to hospital because of the moderate COVID-19 caused by the Omicron variant BA2.0. He presented the initial syndromes including Xerostomia, cough and fever. Chest computed tomography (CT) scanning at admission showed the exudation lesions on lung. The laboratory examination revealed that there are increased C-reactive protein (CRP), Ferritin and erythrocytesedimentationrate (ESR) and decreased white blood cells. INTERVENTIONS: The oral Paxlovid (Nirmatrelvir/Ritonavir) was administrated on second day after admission. OUTCOMES: The syndromes of Xerostomia, cough and fever was improved on third day after use of Paxlovid. The levels of CRP, ESR and counts of white blood cells returned the normal after three days of admission. The chest CT scanned on the third and sixth day after Paxlovid used showed the absorption of lesions. The examination of SARS-COVS viral nucleic acid turned negative at fifth day of admission. LESSONS: As a result, we would consider that Paxlovid is a suitable oral drug for elderly patients with SARS-COV2 even Omicron variant, it’s benefit to improve patient’s symptom and signs and can prevents COVID-19 with the high-risk factors from severe disease, although it didn’t shorten the time for viral nucleic acid to turn negative.
format Online
Article
Text
id pubmed-9665888
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96658882022-11-16 Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report Zhang, Liulu Zhang, Shasha Han, Jing Yi, Yile Zhou, Hourong Li, Jianquan Medicine (Baltimore) 4400 Paxlovid has shown the potential decreasing the hospitalization rate of mild or moderate coronavirus disease 2019 (COVID-19) and death in few of clinical trials, and is expected to the most promising medicine targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SRAS-COV-2). However, there are no enough evidences to show it effectiveness for all patients with SARS-COV-2, especially among elderly patients and newest Omicron variant. PATIENT CONCERNS AND DIAGNOSIS: A 79 year’s old female patient was admitted to hospital because of the moderate COVID-19 caused by the Omicron variant BA2.0. He presented the initial syndromes including Xerostomia, cough and fever. Chest computed tomography (CT) scanning at admission showed the exudation lesions on lung. The laboratory examination revealed that there are increased C-reactive protein (CRP), Ferritin and erythrocytesedimentationrate (ESR) and decreased white blood cells. INTERVENTIONS: The oral Paxlovid (Nirmatrelvir/Ritonavir) was administrated on second day after admission. OUTCOMES: The syndromes of Xerostomia, cough and fever was improved on third day after use of Paxlovid. The levels of CRP, ESR and counts of white blood cells returned the normal after three days of admission. The chest CT scanned on the third and sixth day after Paxlovid used showed the absorption of lesions. The examination of SARS-COVS viral nucleic acid turned negative at fifth day of admission. LESSONS: As a result, we would consider that Paxlovid is a suitable oral drug for elderly patients with SARS-COV2 even Omicron variant, it’s benefit to improve patient’s symptom and signs and can prevents COVID-19 with the high-risk factors from severe disease, although it didn’t shorten the time for viral nucleic acid to turn negative. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9665888/ /pubmed/36397388 http://dx.doi.org/10.1097/MD.0000000000031361 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4400
Zhang, Liulu
Zhang, Shasha
Han, Jing
Yi, Yile
Zhou, Hourong
Li, Jianquan
Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
title Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
title_full Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
title_fullStr Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
title_full_unstemmed Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
title_short Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
title_sort paxlovid administration in elderly patient with covid-19 caused by omicron ba.2.0: a case report
topic 4400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665888/
https://www.ncbi.nlm.nih.gov/pubmed/36397388
http://dx.doi.org/10.1097/MD.0000000000031361
work_keys_str_mv AT zhangliulu paxlovidadministrationinelderlypatientwithcovid19causedbyomicronba20acasereport
AT zhangshasha paxlovidadministrationinelderlypatientwithcovid19causedbyomicronba20acasereport
AT hanjing paxlovidadministrationinelderlypatientwithcovid19causedbyomicronba20acasereport
AT yiyile paxlovidadministrationinelderlypatientwithcovid19causedbyomicronba20acasereport
AT zhouhourong paxlovidadministrationinelderlypatientwithcovid19causedbyomicronba20acasereport
AT lijianquan paxlovidadministrationinelderlypatientwithcovid19causedbyomicronba20acasereport